Relmada Therapeutics to Report Third Quarter 2024 Financial Results on November 7, 2024

GlobeNewswire

05 Nov 2024

RLMD Logo.jpg

CORAL GABLES, Fla., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada”), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced plans to host a conference call and webcast on Thursday, November 7, 2024 at 4:30 PM ET to discuss recent business progress and financial results for the third quarter ended September 30, 2024.

Conference Call and Webcast Information:
Date:		Thursday, November 7, 2024 at 4:30 PM ET
Participant Dial-in (US):		1-800-717-1738
Participant Dial-in (International):		1-646-307-1865
Conference ID Code:		60579
Webcast Access:		Click Here

A replay of the webcast will be available in the Investors section of the Relmada website at https://www.relmada.com/investors/ir-calendar.

About Relmada Therapeutics, Inc.

Relmada Therapeutics is a late-stage biotechnology company addressing diseases of the central nervous system (CNS), with a focus on major depressive disorder (MDD). Relmada's experienced and dedicated team is committed to making a difference in the lives of patients and their families. Relmada's lead program, REL-1017 (esmethadone), is a new chemical entity (NCE) and novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission. REL-1017 is in late-stage development as an adjunctive treatment for MDD in adults. Learn more at www.relmada.com.

Investor Contact:
Tim McCarthy
LifeSci Advisors
Tim@lifesciadvisors.com

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2481557272"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2481557272\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2481557272?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/tFDnGurYmaHVE9baB8jDjw--~B/aD0zMzt3PTEzMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/edd0fedcebb5e5ff70059e418ed8a363","is_english":true,"pubTime":"2024-11-05 05:30","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2481557272","market":"us","top_or_hot":-1,"title":"Relmada Therapeutics to Report Third Quarter 2024 Financial Results on November 7, 2024","media":"GlobeNewswire","content":"<html><body><img hspace=\"5\" src=\"https://s1.yimg.com/uu/api/res/1.2/3hBMc7zSXt24dJpu5a.rzw--/cT03NTthcHBpZD15dmlkZW9mZWVkczs-/https://media.zenfs.com/en/globenewswire.com/864e8ce076842deb8ff51dcb2351bb2e\" title=\"RLMD Logo.jpg\" vspace=\"5\"/>\n<p>CORAL GABLES, Fla., Nov. 04, 2024 (GLOBE NEWSWIRE) -- <a href=\"https://laohu8.com/S/RLMD\">Relmada Therapeutics, Inc.</a> (Nasdaq: RLMD, “Relmada”), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced plans to host a conference call and webcast on Thursday, November 7, 2024 at 4:30 PM ET to discuss recent business progress and financial results for the third quarter ended September 30, 2024.</p>\n<table>\n<tbody>\n<tr>\n<td colspan=\"3\"><strong>Conference Call and Webcast Information</strong>:<br/></td>\n</tr>\n<tr>\n<td>Date:</td>\n<td> </td>\n<td>Thursday, November 7, 2024 at 4:30 PM ET</td>\n</tr>\n<tr>\n<td>Participant Dial-in (US):</td>\n<td> </td>\n<td>1-800-717-1738</td>\n</tr>\n<tr>\n<td>Participant Dial-in (International):</td>\n<td> </td>\n<td>1-646-307-1865</td>\n</tr>\n<tr>\n<td>Conference ID Code:</td>\n<td> </td>\n<td>60579</td>\n</tr>\n<tr>\n<td>Webcast Access:</td>\n<td> </td>\n<td>Click Here</td>\n</tr>\n</tbody>\n</table>\n<p>A replay of the webcast will be available in the Investors section of the Relmada website at https://www.relmada.com/investors/ir-calendar.</p>\n<p><strong>About Relmada <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a>, Inc. </strong></p>\n<p>Relmada Therapeutics is a late-stage biotechnology company addressing diseases of the central nervous system (CNS), with a focus on major depressive disorder (MDD). Relmada's experienced and dedicated team is committed to making a difference in the lives of patients and their families. Relmada's lead program, REL-1017 (esmethadone), is a new chemical entity (NCE) and novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission. REL-1017 is in late-stage development as an adjunctive treatment for MDD in adults. Learn more at www.relmada.com.</p>\n<p><strong>Investor Contact: </strong><br/>Tim McCarthy <br/>LifeSci Advisors <br/>Tim@lifesciadvisors.com<br/><br/><br/></p>\n<br/></body></html>","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Relmada Therapeutics to Report Third Quarter 2024 Financial Results on November 7, 2024</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRelmada Therapeutics to Report Third Quarter 2024 Financial Results on November 7, 2024\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-05 05:30 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/relmada-therapeutics-report-third-quarter-213000937.html><strong>GlobeNewswire</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>CORAL GABLES, Fla., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada”), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), ...</p>\n\n<a href=\"https://finance.yahoo.com/news/relmada-therapeutics-report-third-quarter-213000937.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"RLMD","symbol_name":"Relmada Therapeutics, Inc.","start_time":0,"source_url":"https://finance.yahoo.com/news/relmada-therapeutics-report-third-quarter-213000937.html","article_id":"2481557272","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/tFDnGurYmaHVE9baB8jDjw--~B/aD0zMzt3PTEzMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/edd0fedcebb5e5ff70059e418ed8a363"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2481557272","pubTimestamp":1730755800,"columns":[],"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"Relmada Therapeutics is a late-stage biotechnology company addressing diseases of the central nervous system , with a focus on major depressive disorder . Relmada's experienced and dedicated team is committed to making a difference in the lives of patients and their families. Relmada's lead program, REL-1017 , is a new chemical entity  and novel NMDA receptor  channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission. REL-1017 is in late-stage development as an adjunctive treatment for MDD in adults. Learn more at www.relmada.com.","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"RLMD":"Relmada Therapeutics, Inc.","BK4007":"制药","LENZ":"Therapeutics","ABVC":"ABVC BioPharma, Inc.","CNS":"科恩-斯蒂尔斯金融","BK4139":"生物科技","BK4135":"资产管理与托管银行"},"translate_title":"Relmada Therapeutics将于2024年11月7日报告2024年第三季度财务业绩","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CNS":1,"LENZ":1,"RLMD":0.9,"ABVC":0.61},"content_text":"CORAL GABLES, Fla., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada”), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced plans to host a conference call and webcast on Thursday, November 7, 2024 at 4:30 PM ET to discuss recent business progress and financial results for the third quarter ended September 30, 2024.\n\n\n\nConference Call and Webcast Information:\n\n\nDate:\n \nThursday, November 7, 2024 at 4:30 PM ET\n\n\nParticipant Dial-in (US):\n \n1-800-717-1738\n\n\nParticipant Dial-in (International):\n \n1-646-307-1865\n\n\nConference ID Code:\n \n60579\n\n\nWebcast Access:\n \nClick Here\n\n\n\nA replay of the webcast will be available in the Investors section of the Relmada website at https://www.relmada.com/investors/ir-calendar.\nAbout Relmada Therapeutics, Inc. \nRelmada Therapeutics is a late-stage biotechnology company addressing diseases of the central nervous system (CNS), with a focus on major depressive disorder (MDD). Relmada's experienced and dedicated team is committed to making a difference in the lives of patients and their families. Relmada's lead program, REL-1017 (esmethadone), is a new chemical entity (NCE) and novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission. REL-1017 is in late-stage development as an adjunctive treatment for MDD in adults. Learn more at www.relmada.com.\nInvestor Contact: Tim McCarthy LifeSci Advisors Tim@lifesciadvisors.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1}}}